Funding for this research was provided by:
Received: 25 September 2018
Accepted: 30 January 2019
First Online: 20 February 2019
Ethics approval and consent to participate
: The trial was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written informed consent as approved by the institutional review board or ethics committee.
: All patients provided written informed consent for publication of information resulting from the trial without any personally identifying information.
: VS has received consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, CORRONA, Crescendo, EMD Serono, Genentech/Roche, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Protagen, Regeneron, Samsung, Sandoz, Sanofi and UCB.SD and NC are employees of Roche Products Ltd.KT is an employee of Genentech and owns shares in Roche.MK was an employee of Genentech at the time of the study.JHS has received grants and consulting fees from Roche and Genentech.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.